{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:51:08Z","timestamp":1791600668927,"version":"4.3.4"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Prim. Care Respir. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Non-tuberculous Mycobacterial Pulmonary Disease (NTM-PD) is a chronic disease characterised by progressive inflammatory lung damage due to infection by non-tuberculous mycobacteria (NTM). Global prevalence of NTM-PD is generally low but is rising, likely due to a combination of increased surveillance, increasing multimorbidity and improved diagnostic techniques. Most disease is caused by <jats:italic>Mycobacterium avium<\/jats:italic> complex species. NTM-PD can be challenging to both diagnose and manage but given the risk of untreated disease and the challenges around drug treatments, it is vital that all healthcare professionals involved in primary care consider NTM-PD at the earliest opportunity. In particular, NTM-PD should be considered where there are respiratory symptoms in the setting of pre-existing chronic lung disease such as chronic obstructive pulmonary disease (COPD) and bronchiectasis. Early suspicion should lead to appropriate primary screening measures. This article discusses the relevance of NTM-PD today, risk factors for developing disease, pathways from clinical presentation to referral to specialist care, and discusses management and drug treatments. A flow diagram of a screening process is presented as a guideline for best practice from a United Kingdom perspective.<\/jats:p>","DOI":"10.1038\/s41533-024-00403-9","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T17:03:57Z","timestamp":1734800637000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A practical guide to the diagnosis and management of suspected Non-tuberculous Mycobacterial Pulmonary Disease (NTM-PD) in the United Kingdom"],"prefix":"10.1038","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-119X","authenticated-orcid":false,"given":"D. J.","family":"Dhasmana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Whitaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"van der Laan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"key":"403_CR1","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1378\/chest.15-0458","volume":"148","author":"PJ McShane","year":"2015","unstructured":"McShane, P. J. & Glassroth, J. Pulmonary disease due to nontuberculous mycobacteria: current state and new insights. Chest 148, 1517\u20131527 (2015).","journal-title":"Chest"},{"key":"403_CR2","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thx.2010.136119","volume":"65","author":"MC Pasteur","year":"2010","unstructured":"Pasteur, M. C., Bilton, D. & Hill, A. T. British Thoracic Society Guideline for non-CF bronchiectasis. Thorax 65, i1\u2013i58 (2010).","journal-title":"Thorax"},{"key":"403_CR3","doi-asserted-by":"publisher","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","volume":"56","author":"CL Daley","year":"2020","unstructured":"Daley, C. L. et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Eur. Respir. J. 56, 2000535 (2020).","journal-title":"Eur. Respir. J."},{"key":"403_CR4","first-page":"301","volume":"18","author":"S Dalvi","year":"2018","unstructured":"Dalvi, S. & Das, P. Prosthetic heart valve surgery and potential risk of developing mycobacterium chimaera endocarditis. Clin. Med. Res. 18, 301\u2013303 (2018).","journal-title":"Clin. Med. Res."},{"key":"403_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","volume":"175","author":"DE Griffith","year":"2007","unstructured":"Griffith, D. E. et al. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175, 367\u2013416 (2007).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"403_CR6","doi-asserted-by":"publisher","first-page":"e3978","DOI":"10.1097\/MD.0000000000003978","volume":"95","author":"SJ Hong","year":"2016","unstructured":"Hong, S. J., Kim, T. J., Lee, J. H. & Park, J. S. Nontuberculous mycobacterial pulmonary disease mimicking lung cancer: clinicoradiologic features and diagnostic implications. Medicine 95, e3978 (2016).","journal-title":"Medicine"},{"key":"403_CR7","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.3390\/jcm10122736","volume":"10","author":"S Dettmer","year":"2021","unstructured":"Dettmer, S. et al. Computed tomography in adults with bronchiectasis and nontuberculous mycobacterial pulmonary disease: typical imaging findings. J. Clin. Med. 10, 2736 (2021).","journal-title":"J. Clin. Med."},{"key":"403_CR8","doi-asserted-by":"publisher","first-page":"809014","DOI":"10.1155\/2015\/809014","volume":"2015","author":"S Faria","year":"2015","unstructured":"Faria, S., Joao, I. & Jordao, L. General overview on nontuberculous mycobacteria, biofilms, and human infection. J. Pathogens 2015, 809014 (2015).","journal-title":"J. Pathogens"},{"key":"403_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/srep45258","volume":"7","author":"T Fedrizzi","year":"2017","unstructured":"Fedrizzi, T. et al. Genomic characterization of nontuberculous mycobacteria. Sci. Rep. 7, 45258 (2017).","journal-title":"Sci. Rep."},{"key":"403_CR10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41579-020-0331-1","volume":"18","author":"MD Johansen","year":"2020","unstructured":"Johansen, M. D., Herrmann, J. L. & Kremer, L. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat. Rev. Microbiol. 18, 392\u2013407 (2020).","journal-title":"Nat. Rev. Microbiol."},{"key":"403_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3389\/fimmu.2020.00303","volume":"11","author":"CN Ratnatunga","year":"2020","unstructured":"Ratnatunga, C. N. et al. The rise of non-tuberculosis mycobacterial lung disease. Front. Immunol. 11, 303 (2020).","journal-title":"Front. Immunol."},{"key":"403_CR12","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1164\/rccm.201205-0913OC","volume":"186","author":"J Adjemian","year":"2012","unstructured":"Adjemian, J. et al. Spatial clusters of nontuberculous mycobacterial lung disease in the United States. Am. J. Respir. Crit. Care Med. 186, 553\u2013558 (2012).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"403_CR13","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.3201\/eid2609.200749","volume":"26","author":"SG Dean","year":"2020","unstructured":"Dean, S. G. et al. Mycobacterial testing trends, United States, 2009-2015. Emerg. Infect. Dis. 26, 2243\u20132246 (2020).","journal-title":"Emerg. Infect. Dis."},{"key":"403_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-10-612","volume":"10","author":"JE Moore","year":"2010","unstructured":"Moore, J. E., Kruijshaar, M. E., Ormerod, L. P., Drobniewski, F. & Abubakar, I. Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995-2006. BMC Public Health 10, 612 (2010).","journal-title":"BMC Public Health"},{"key":"403_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12879-016-1521-3","volume":"16","author":"NM Shah","year":"2016","unstructured":"Shah, N. M. et al. Pulmonary Mycobacterium avium-intracellulare is the main driver of the rise in non-tuberculous mycobacteria incidence in England, Wales and Northern Ireland, 2007-2012. BMC Infect. Dis. 16, 195 (2016).","journal-title":"BMC Infect. Dis."},{"key":"403_CR16","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1183\/09031936.00149212","volume":"42","author":"W Hoefsloot","year":"2013","unstructured":"Hoefsloot, W. et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur. Respir. J. 42, 1604\u20131613 (2013).","journal-title":"Eur. Respir. J."},{"key":"403_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0606-6","volume":"14","author":"MA Lake","year":"2016","unstructured":"Lake, M. A., Ambrose, L. R., Lipman, M. C. & Lowe, D. M. \u2018\u201cWhy me, why now?\u201d Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection. BMC Med. 14, 54 (2016).","journal-title":"BMC Med."},{"key":"403_CR18","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.chest.2023.06.014","volume":"164","author":"MR Loebinger","year":"2023","unstructured":"Loebinger, M. R. et al. Risk factors for nontuberculous mycobacterial pulmonary disease: a systematic literature review and meta-analysis. Chest 164, 1115\u20131124 (2023).","journal-title":"Chest"},{"key":"403_CR19","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.rmed.2011.08.004","volume":"105","author":"M Mehta","year":"2011","unstructured":"Mehta, M. & Marras, T. K. Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease. Respir. Med. 105, 1718\u20131725 (2011).","journal-title":"Respir. Med."},{"key":"403_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07054-6","volume":"22","author":"RA Blakney","year":"2022","unstructured":"Blakney, R. A. et al. The 6-minute walk test predicts mortality in a pulmonary nontuberculous mycobacteria-predominant bronchiectasis cohort. BMC Infect. Dis. 22, 75 (2022).","journal-title":"BMC Infect. Dis."},{"key":"403_CR21","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12879-018-3113-x","volume":"18","author":"R Diel","year":"2018","unstructured":"Diel, R., Lipman, M. & Hoefsloot, W. High mortality in patients with Mycobacterium avium complex lung disease: a systematic review. BMC Infect. Dis. 18, 206 (2018).","journal-title":"BMC Infect. Dis."},{"key":"403_CR22","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1164\/rccm.201107-1203OC","volume":"185","author":"M Hayashi","year":"2012","unstructured":"Hayashi, M. et al. Prognostic factors of 634 HIV-negative patients with mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. 185, 575\u2013583 (2012).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"403_CR23","doi-asserted-by":"publisher","first-page":"1900798","DOI":"10.1183\/13993003.00798-2019","volume":"55","author":"BW Jhun","year":"2019","unstructured":"Jhun, B. W. et al. Prognostic factors associated with long-term mortality in 1,445 patients with non-tuberculous mycobacterial pulmonary disease. Eur. Respir. J. 55, 1900798 (2019).","journal-title":"Eur. Respir. J."},{"key":"403_CR24","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3201\/eid2303.161927","volume":"23","author":"TK Marras","year":"2017","unstructured":"Marras, T. K. et al. Pulmonary nontuberculous mycobacteria-associated deaths, Ontario, Canada, 2001-2013. Emerg. Infect. Dis. 23, 468\u2013476 (2017).","journal-title":"Emerg. Infect. Dis."},{"key":"403_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10096-013-1962-1","volume":"33","author":"HB Xu","year":"2014","unstructured":"Xu, H. B., Jiang, R. H. & Li, L. Treatment outcomes for Mycobacterium avium complex: a systematic review and meta-analysis. Eur. J. Clin. Microbiol. Infect. Dis. 33, 347\u2013358 (2014).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"403_CR26","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","volume":"174","author":"DE Griffith","year":"2006","unstructured":"Griffith, D. E. et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. 174, 928\u2013934 (2006).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"403_CR27","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1128\/AAC.02281-12","volume":"57","author":"WJ Koh","year":"2013","unstructured":"Koh, W. J. et al. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. Antimicrob. Agents Chemother. 57, 2281\u20132285 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"403_CR28","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1378\/chest.13-2538","volume":"146","author":"RJJ Wallace","year":"2014","unstructured":"Wallace, R. J. J. et al. Macrolide\/azalide therapy for nodular\/bronchiectatic Mycobacterium avium complex lung disease. Chest 146, 276\u2013282 (2014).","journal-title":"Chest"},{"key":"403_CR29","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1164\/rccm.201502-0387OC","volume":"192","author":"EP Szymanski","year":"2015","unstructured":"Szymanski, E. P. et al. Pulmonary nontuberculous mycobacterial infection. a multisystem, multigenic disease. Am J. Respir. Crit. Care Med. 192, 618\u2013628 (2015).","journal-title":"Am J. Respir. Crit. Care Med."},{"key":"403_CR30","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jiac.2020.04.013","volume":"26","author":"T Kitazawa","year":"2020","unstructured":"Kitazawa, T. et al. Recent increase in non-tuberculous mycobacterial infection in patients with connective tissue diseases in Japan. J. Infect. Chemother. 26, 941\u2013945 (2020).","journal-title":"J. Infect. Chemother."},{"key":"403_CR31","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1513\/AnnalsATS.201805-325RL","volume":"16","author":"K Teerapuncharoen","year":"2019","unstructured":"Teerapuncharoen, K. et al. Acquired cystic fibrosis transmembrane conductance regulator dysfunction and radiographic bronchiectasis in current and former smokers: a cross-sectional study. Ann. ATS 16, 150\u2013153 (2019).","journal-title":"Ann. ATS"},{"key":"403_CR32","doi-asserted-by":"publisher","first-page":"190068","DOI":"10.1183\/16000617.0068-2019","volume":"29","author":"SD Patel","year":"2020","unstructured":"Patel, S. D., Bono, T. R., Rowe, S. M. & Solomon, G. M. CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways. Eur. Respir. Re.v 29, 190068 (2020).","journal-title":"Eur. Respir. Re.v"},{"key":"403_CR33","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1164\/rccm.200805-686OC","volume":"178","author":"RD Kim","year":"2008","unstructured":"Kim, R. D. et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am. J. Respir. Crit. Care Med. 178, 1066\u20131074 (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"403_CR34","first-page":"1674","volume":"13","author":"KN Olivier","year":"2016","unstructured":"Olivier, K. N. Lady Windermere dissected: more form than fastidious. Ann. Am. Thorac. Soc. 13, 1674\u20131676 (2016).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"403_CR35","first-page":"210","volume":"6","author":"MM Johnson","year":"2014","unstructured":"Johnson, M. M. & Odell, J. A. Nontuberculous mycobacterial pulmonary infections. J. Thorac. Dis. 6, 210\u2013220 (2014).","journal-title":"J. Thorac. Dis."},{"key":"403_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-231","volume":"13","author":"FC Ringshausen","year":"2013","unstructured":"Ringshausen, F. C. et al. Burden and trends of hospitalisations associated with pulmonary non-tuberculous mycobacterial infections in Germany, 2005-2011. BMC Infect. Dis. 13, 231 (2013).","journal-title":"BMC Infect. Dis."},{"key":"403_CR37","doi-asserted-by":"publisher","first-page":"16300","DOI":"10.1038\/s41598-017-16559-z","volume":"7","author":"HL Huang","year":"2017","unstructured":"Huang, H. L. et al. Epidemiology and predictors of NTM pulmonary infection in Taiwan - a retrospective, five-year multicenter study. Sci. Rep. 7, 16300 (2017).","journal-title":"Sci. Rep."},{"key":"403_CR38","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2174\/1573398X16999200901185724","volume":"16","author":"M Mozdourian","year":"2021","unstructured":"Mozdourian, M. & Khodashahi, R. Association between the use of inhaled corticosteroids and pulmonary nontuberculous mycobacterial infection: a systematic review. Curr. Respir. Med. Rev. 16, 113\u2013122 (2021).","journal-title":"Curr. Respir. Med. Rev."},{"key":"403_CR39","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00508-021-01923-x","volume":"133","author":"G Glodic","year":"2021","unstructured":"Glodic, G. et al. Risk factors for nontuberculous mycobacterial pulmonary disease (NTM-PD) in Croatia. Wien. Klin. Wochenschr. 133, 1195\u20131200 (2021).","journal-title":"Wien. Klin. Wochenschr."},{"key":"403_CR40","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.3201\/eid2908.230378","volume":"29","author":"C Mejia-Chew","year":"2023","unstructured":"Mejia-Chew, C. et al. Spatial epidemiologic analysis and risk factors for nontuberculous mycobacteria infections, Missouri, USA, 2008-2019. Emerg. Infect. Dis. 29, 1540\u20131546 (2023).","journal-title":"Emerg. Infect. Dis."},{"key":"403_CR41","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ijmyco.2016.02.006","volume":"5","author":"S Hamada","year":"2016","unstructured":"Hamada, S. et al. Impact of industrial structure and soil exposure on the regional variations in pulmonary nontuberculous mycobacterial disease prevalence. Int. J. Mycobacteriol. 5, 170\u2013176 (2016).","journal-title":"Int. J. Mycobacteriol."},{"key":"403_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4078-0","volume":"19","author":"HJ Kim","year":"2019","unstructured":"Kim, H. J. et al. Nontuberculous mycobacterial pulmonary disease diagnosed by two methods: a prospective cohort study. BMC Infect. Dis. 19, 468 (2019).","journal-title":"BMC Infect. Dis."},{"key":"403_CR43","first-page":"243","volume":"8","author":"V Pravosud","year":"2021","unstructured":"Pravosud, V. et al. Symptom burden and medication use among patients with nontuberculous mycobacterial lung disease. Chronic Obstr. Pulm. Dis. 8, 243\u2013254 (2021).","journal-title":"Chronic Obstr. Pulm. Dis."},{"key":"403_CR44","doi-asserted-by":"publisher","first-page":"00737","DOI":"10.1183\/23120541.00737-2022","volume":"9","author":"MR Loebinger","year":"2023","unstructured":"Loebinger, M. R., van der Laan, R., Obradovic, M. & van Ingen, J. Global survey of physician testing practices for nontuberculous mycobacteria. ERJ Open Res. 9, 00737\u201302022 (2023).","journal-title":"ERJ Open Res."},{"key":"403_CR45","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12890-018-0675-8","volume":"18","author":"SA Cowman","year":"2018","unstructured":"Cowman, S. A. et al. Latent class analysis to define radiological subgroups in pulmonary nontuberculous mycobacterial disease. BMC Pulm. Med. 18, 145 (2018).","journal-title":"BMC Pulm. Med."},{"key":"403_CR46","first-page":"2358","volume":"56","author":"JD Chalmers","year":"2020","unstructured":"Chalmers, J. D. et al. Radiological features of NTM pulmonary disease in patients with bronchiectasis. Eur. Respir. J. 56, 2358 (2020).","journal-title":"Eur. Respir. J."},{"key":"403_CR47","first-page":"PA348","volume":"52","author":"M Loebinger","year":"2018","unstructured":"Loebinger, M. et al. Characteristics of patients with pulmonary non-tuberculous mycobacterial infection in bronchiectasis: data from the EMBARC registry. Eur. Respir. J. 52, PA348 (2018).","journal-title":"Eur. Respir. J."},{"key":"403_CR48","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","volume":"72","author":"CS Haworth","year":"2017","unstructured":"Haworth, C. S. et al. British Thoracic Society Guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 72, ii1\u2013ii64 (2017).","journal-title":"Thorax"},{"key":"403_CR49","unstructured":"NICE. Cystic Fibrosis: Diagnosis and Management (NICE guidelines, 2017)."},{"key":"403_CR50","doi-asserted-by":"publisher","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","volume":"50","author":"E Polverino","year":"2017","unstructured":"Polverino, E. et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur. Respir. J. 50, 1700629 (2017).","journal-title":"Eur. Respir. J."},{"key":"403_CR51","unstructured":"NICE. Chronic Obstructive Pulmonary Disease in over 16s: Diagnosis and Management (NICE guidelines, 2018)."},{"key":"403_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4046\/trd.2014.77.1.1","volume":"77","author":"YS Kwon","year":"2014","unstructured":"Kwon, Y. S. & Koh, W. J. Diagnosis of pulmonary tuberculosis and nontuberculous mycobacterial lung disease in Korea. Tuberc. Respir. Dis. 77, 1\u20135 (2014).","journal-title":"Tuberc. Respir. Dis."},{"key":"403_CR53","doi-asserted-by":"publisher","first-page":"e01480","DOI":"10.1128\/JCM.01480-17","volume":"56","author":"TP Quan","year":"2018","unstructured":"Quan, T. P. et al. Evaluation of whole-genome sequencing for mycobacterial species identification and drug susceptibility testing in a clinical setting: a large-scale prospective assessment of performance against line probe assays and phenotyping. J. Clin. Microbiol. 56, e01480\u201317 (2018).","journal-title":"J. Clin. Microbiol."},{"key":"403_CR54","doi-asserted-by":"publisher","first-page":"2002272","DOI":"10.1183\/13993003.02272-2020","volume":"57","author":"E Tagliani","year":"2021","unstructured":"Tagliani, E. et al. Use of a whole genome sequencing-based approach for mycobacterium tuberculosis surveillance in Europe in 2017-2019: an ECDC Pilot Study. Eur. Respir. J. 57, 2002272 (2021).","journal-title":"Eur. Respir. J."},{"key":"403_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05315-7","volume":"12","author":"D Rodriguez-Temporal","year":"2022","unstructured":"Rodriguez-Temporal, D. et al. Multicentre study on the reproducibility of MALDI-TOF MS for nontuberculous mycobacteria identification. Sci. Rep. 12, 1237 (2022).","journal-title":"Sci. Rep."},{"key":"403_CR56","doi-asserted-by":"publisher","first-page":"e1000","DOI":"10.1016\/j.ijid.2013.03.018","volume":"17","author":"M Mirsaeidi","year":"2013","unstructured":"Mirsaeidi, M., Hadid, W., Ericsoussi, B., Rodgers, D. & Sadikot, R. T. Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis. Int. J. Infect. Dis. 17, e1000\u2013e1004 (2013).","journal-title":"Int. J. Infect. Dis."},{"key":"403_CR57","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4046\/trd.2016.79.2.74","volume":"79","author":"YJ Ryu","year":"2016","unstructured":"Ryu, Y. J., Koh, W. J. & Daley, C. L. Diagnosis and treatment of nontuberculous mycobacterial lung disease: clinicians' perspectives. Tuberc. Respir. Dis. 79, 74\u201384 (2016).","journal-title":"Tuberc. Respir. Dis."},{"key":"403_CR58","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.2147\/DDDT.S146111","volume":"14","author":"O Khan","year":"2020","unstructured":"Khan, O. & Chaudary, N. The use of amikacin liposome inhalation suspension (Arikayce) in the treatment of refractory nontuberculous mycobacterial lung disease in adults. Drug Des. Devel. Ther. 14, 2287\u20132294 (2020).","journal-title":"Drug Des. Devel. Ther."},{"key":"403_CR59","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1440-1843.2008.01408.x","volume":"14","author":"RM Thomson","year":"2009","unstructured":"Thomson, R. M. & Yew, W. W. When and how to treat pulmonary non-tuberculous mycobacterial diseases. Respirology 14, 12\u201326 (2009).","journal-title":"Respirology"},{"key":"403_CR60","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.drup.2012.04.001","volume":"15","author":"J van Ingen","year":"2012","unstructured":"van Ingen, J., Boeree, M. J., van Soolingen, D. & Mouton, J. W. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist. Updat. 15, 149\u2013161 (2012).","journal-title":"Drug Resist. Updat."},{"key":"403_CR61","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","volume":"71","author":"RA Floto","year":"2016","unstructured":"Floto, R. A. et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 71, i1\u2013i22 (2016).","journal-title":"Thorax"},{"key":"403_CR62","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1513\/AnnalsATS.201304-085OC","volume":"11","author":"J Adjemian","year":"2014","unstructured":"Adjemian, J. et al. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. Ann. Am. Thorac. Soc. 11, 9\u201316 (2014).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"403_CR63","doi-asserted-by":"publisher","first-page":"00623","DOI":"10.1183\/23120541.00623-2021","volume":"8","author":"TK Marras","year":"2022","unstructured":"Marras, T. K. et al. Amikacin liposome inhalation suspension clinical benefit-risk assessment for refractory Mycobacterium avium complex lung disease. ERJ Open Res. 8, 00623\u201302021 (2022).","journal-title":"ERJ Open Res."},{"key":"403_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-34576-z","volume":"13","author":"H Hwang","year":"2023","unstructured":"Hwang, H., Lee, J. K., Heo, E. Y., Kim, D. K. & Lee, H. W. The factors associated with mortality and progressive disease of nontuberculous mycobacterial lung disease: a systematic review and meta-analysis. Sci. Rep. 13, 7348 (2023).","journal-title":"Sci. Rep."},{"key":"403_CR65","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12890-016-0349-3","volume":"17","author":"SJ Kim","year":"2017","unstructured":"Kim, S. J. et al. Characteristics associated with progression in patients with of nontuberculous mycobacterial lung disease : a prospective cohort study. BMC Pulm. Med. 17, 5 (2017).","journal-title":"BMC Pulm. Med."},{"key":"403_CR66","doi-asserted-by":"publisher","first-page":"1600537","DOI":"10.1183\/13993003.00537-2016","volume":"49","author":"JA Hwang","year":"2017","unstructured":"Hwang, J. A., Kim, S., Jo, K. W. & Shim, T. S. Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course. Eur. Respir. J. 49, 1600537 (2017).","journal-title":"Eur. Respir. J."},{"key":"403_CR67","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/cid\/cix479","volume":"65","author":"SW Pan","year":"2017","unstructured":"Pan, S. W. et al. Microbiological persistence in patients with Mycobacterium avium complex lung disease: the predictors and the impact on radiographic progression. Clin. Infect. Dis. 65, 927\u2013934 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"403_CR68","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.chest.2016.06.005","volume":"150","author":"HY Park","year":"2016","unstructured":"Park, H. Y. et al. Lung function decline according to clinical course in nontuberculous mycobacterial lung disease. Chest 150, 1222\u20131232 (2016).","journal-title":"Chest"},{"key":"403_CR69","doi-asserted-by":"publisher","first-page":"1602503","DOI":"10.1183\/13993003.02503-2016","volume":"50","author":"WJ Koh","year":"2017","unstructured":"Koh, W. J. et al. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. Eur. Respir. J. 50, 1602503 (2017).","journal-title":"Eur. Respir. J."},{"key":"403_CR70","doi-asserted-by":"publisher","first-page":"6473629","DOI":"10.1155\/2018\/6473629","volume":"2018","author":"P Chetchotisakd","year":"2018","unstructured":"Chetchotisakd, P., Anunnatsiri, S., Nanagara, R., Nithichanon, A. & Lertmemongkolchai, G. Intravenous cyclophosphamide therapy for anti-IFN-gamma autoantibody-associated Mycobacterium abscessus infection. J. Immunol. Res. 2018, 6473629 (2018).","journal-title":"J. Immunol. Res."}],"updated-by":[{"DOI":"10.1038\/s41533-025-00423-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000}},{"DOI":"10.1038\/s41533-025-00439-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000}}],"container-title":["npj Primary Care Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41533-024-00403-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41533-024-00403-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41533-024-00403-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T07:02:09Z","timestamp":1751785329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41533-024-00403-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["403"],"URL":"https:\/\/doi.org\/10.1038\/s41533-024-00403-9","relation":{},"ISSN":["2055-1010"],"issn-type":[{"value":"2055-1010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,21]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41533-025-00423-z","URL":"https:\/\/doi.org\/10.1038\/s41533-025-00423-z","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41533-025-00439-5","URL":"https:\/\/doi.org\/10.1038\/s41533-025-00439-5","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We declare that one or more of the authors have a competing interest as defined by Nature Portfolio, as follows: P.W. has received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from Insmed Incorporated. R.v.d.L. was an employee of Insmed BV at the time of manuscript development and holds stock in the company. F.F. has received support for attending meetings and\/or travel from Chiesi Ltd. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}